DK1409525T3 - Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme - Google Patents

Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme

Info

Publication number
DK1409525T3
DK1409525T3 DK02745024T DK02745024T DK1409525T3 DK 1409525 T3 DK1409525 T3 DK 1409525T3 DK 02745024 T DK02745024 T DK 02745024T DK 02745024 T DK02745024 T DK 02745024T DK 1409525 T3 DK1409525 T3 DK 1409525T3
Authority
DK
Denmark
Prior art keywords
tad
inhibitor
hpv
complex
binding pocket
Prior art date
Application number
DK02745024T
Other languages
Danish (da)
English (en)
Inventor
Dale R Cameron
Jacques Archambault
Yong Wang
Christiane Yoakim
Peter White
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1409525T3 publication Critical patent/DK1409525T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK02745024T 2001-07-12 2002-07-12 Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme DK1409525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30441201P 2001-07-12 2001-07-12
PCT/CA2002/001058 WO2003006495A2 (fr) 2001-07-12 2002-07-12 Co-cristal de domaine/d'inhibiteur de transactivation de papillomavirus e2 humain, et coordonnees de radiographie definissant la poche de liaison avec l'inhibiteur

Publications (1)

Publication Number Publication Date
DK1409525T3 true DK1409525T3 (da) 2007-02-05

Family

ID=23176405

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02745024T DK1409525T3 (da) 2001-07-12 2002-07-12 Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme
DK06012247.0T DK1695980T3 (da) 2001-07-12 2002-07-12 Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06012247.0T DK1695980T3 (da) 2001-07-12 2002-07-12 Co-krystal af human papillomavirus E2 transaktiveringsdomæne/inhibitor og røntgenkoordinater, der definerer inhibitor-bindingslommen

Country Status (14)

Country Link
US (1) US7167801B2 (fr)
EP (2) EP1409525B1 (fr)
JP (1) JP4602665B2 (fr)
AT (2) ATE465414T1 (fr)
AU (1) AU2002317122B2 (fr)
CA (1) CA2448482C (fr)
DE (2) DE60236114D1 (fr)
DK (2) DK1409525T3 (fr)
ES (2) ES2342309T3 (fr)
HU (1) HUP0402069A3 (fr)
IL (2) IL159150A0 (fr)
MX (1) MXPA04000271A (fr)
NZ (1) NZ531068A (fr)
WO (1) WO2003006495A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219767A1 (en) * 2003-05-06 2007-09-20 Carter Daniel C Atomic coordinates of albumin drug complexes and method of use of pharmaceutical development
EP1633861B1 (fr) * 2003-05-26 2009-11-04 Biotie Therapies Corp. Vap-1 cristalline et ses utilisations
EP1684705A4 (fr) * 2003-11-03 2008-02-20 New Century Pharmaceuticals Sites de liaison a l'albumine permettant d'evaluer des interactions medicamenteuses et procedes d'evaluation ou de conception de medicaments fondes sur les proprietes de liaison a l'albumine de ces derniers
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN112891520A (zh) * 2021-04-13 2021-06-04 吉林省国大生物工程有限公司 一种预防和控制人乳头瘤病毒感染(hpv)的活性生物蛋白的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500245A (ja) 1991-10-11 1995-01-12 カイロン コーポレーション パピローマウイルスの複製の阻害剤を同定する方法および組成物
IL139270A0 (en) 1998-05-01 2001-11-25 Boehringer Ingelheim Ca Ltd Preparation of human papillomavirus e1 having helicase activity and method therefor
ATE235509T1 (de) 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
WO2000075182A1 (fr) * 1999-06-04 2000-12-14 Akira Kaji Cristal de proteine du facteur de recyclage ribosomique (rrf) et son application sur la base de donnees de structure tridimensionnelles provenant du cristal
GB9921938D0 (en) 1999-09-17 1999-11-17 Univ York Target for antiviral therapy
WO2001037194A2 (fr) * 1999-11-16 2001-05-25 Vertex Pharmaceuticals Incorporated Compositions cristallisables comprenant une caspase-7
EP1345943B1 (fr) 2000-12-18 2007-03-21 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs du papillomavirus

Also Published As

Publication number Publication date
DE60215658D1 (de) 2006-12-07
US20030082769A1 (en) 2003-05-01
EP1695980A2 (fr) 2006-08-30
US7167801B2 (en) 2007-01-23
HUP0402069A3 (en) 2012-09-28
CA2448482C (fr) 2011-12-06
ES2342309T3 (es) 2010-07-05
HUP0402069A2 (hu) 2005-01-28
JP2005512954A (ja) 2005-05-12
MXPA04000271A (es) 2005-03-07
EP1409525B1 (fr) 2006-10-25
ES2274051T3 (es) 2007-05-16
WO2003006495A2 (fr) 2003-01-23
ATE465414T1 (de) 2010-05-15
IL159150A0 (en) 2004-06-01
AU2002317122B2 (en) 2007-03-15
IL159150A (en) 2009-09-01
DE60236114D1 (de) 2010-06-02
EP1695980B1 (fr) 2010-04-21
EP1409525A2 (fr) 2004-04-21
NZ531068A (en) 2006-06-30
CA2448482A1 (fr) 2003-01-23
EP1695980A3 (fr) 2006-09-06
DE60215658T2 (de) 2007-12-27
DK1695980T3 (da) 2010-08-02
ATE343588T1 (de) 2006-11-15
WO2003006495A3 (fr) 2003-07-31
JP4602665B2 (ja) 2010-12-22

Similar Documents

Publication Publication Date Title
AU2003301959A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
ATE503764T1 (de) Inhibitoren des hepatitis-c-virus
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
DE50312257D1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
EA200400183A1 (ru) Кристаллы, содержащие соль n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида с яблочной кислотой, способы их получения и их композиции
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
ATE172968T1 (de) Substituierte azadioxacycloalkene und ihre verwendung als fungizide
PE20040644A1 (es) Nuevos derivados de quinuclidina-amina
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ATE431340T1 (de) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1- piperidincarboxamid-derivate und verwandte verbindungen als cgrp-antagonisten zur behandlung von kopfschmerzen
CY1106721T1 (el) Μεθοδος παρασκευης υψηλης καθαροτητας περινδοπριλης και ενδιαμεσα χρησιμα στη συνθεση
ATE234282T1 (de) Polymorphe verbindungen
DE50004569D1 (de) Verfahren zur gewinnung von phytosterinen durch kristallisation aus verminderten mengen methanols
DK1409525T3 (da) Humant papillomavirus-E2-transaktiveringsdomæne/inhibitor-co-krystal og röntgenkoordinater, der definerer den inhibitorbindende lomme
DE60113243D1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
ATE346029T1 (de) 3,3,4,4-tetrafluorcyclopentanverbindungen als komponenten flüssigkristalliner medien
TR200503397T1 (tr) Levetirasetam'ın yeni kristal formları.
DE60312953D1 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
TR200503398T1 (tr) Trandolapril'in yeni kristal formları.
DK0691986T3 (da) Hidtil ukendte fremgangsmåder og mellemproduktforbindelser til fremstillingen af blodpladeglycoprotein IIb/IIIa-inhibitorer
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
TH57580B (th) วิธีการผลิตผลึก
RU95105969A (ru) Производные диоксциклобутена, способ получения, фармацевтическая композиция, способ лечения гипертонии